


PHARMACEUTICAL 2021



Morphic Holding Inc. Rank 126 of 409







PHARMACEUTICAL 2021



Morphic Holding Inc. Rank 126 of 409

The relative strengths and weaknesses of Morphic Holding Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Morphic Holding Inc. compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 99% points. The greatest weakness of Morphic Holding Inc. is the variable Research and Development, reducing the Economic Capital Ratio by 56% points.

The company's Economic Capital Ratio, given in the ranking table, is -14%, being 341% points above the market average of -355%.

Input Variable	Value in 1000 USD
Assets, Current	239,435
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	39,438
Liabilities, Non-Current	0
Other Assets	341
Other Compr. Net Income	-65
Other Expenses	-570
Other Liabilities	57,747
Other Net Income	1,611
Property and Equipment	2,606
Research and Development	73,630
Revenues	44,945
Selling, General and Administrative Expense	18,495

Output Variable	Value in 1000 USD
Assets	242,382
Liabilities	97,185
Expenses	91,555
Stockholders Equity	145,197
Net Income	-44,999
Comprehensive Net Income	-45,032
Economic Capital Ratio	-14%

